muraglitazar has been researched along with bromodeoxyuridine in 1 studies
| Studies (muraglitazar) | Trials (muraglitazar) | Recent Studies (post-2010) (muraglitazar) | Studies (bromodeoxyuridine) | Trials (bromodeoxyuridine) | Recent Studies (post-2010) (bromodeoxyuridine) |
|---|---|---|---|---|---|
| 85 | 10 | 25 | 13,164 | 71 | 1,816 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, LE; Cano, M; Cohen, SM; Dominick, MA; Moehlenkamp, JD; Sanderson, TP; Schilling, BE; Tannehill-Gregg, S; Van Vleet, T; Waites, CR; White, MR | 1 |
1 other study(ies) available for muraglitazar and bromodeoxyuridine
| Article | Year |
|---|---|
Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.
Topics: Animals; Antimetabolites; Apoptosis; Area Under Curve; Bromodeoxyuridine; Calcium; Carcinogens; Cell Proliferation; Citrates; Electrolytes; Glycine; Hydrogen-Ion Concentration; Immunohistochemistry; Male; Microscopy, Electron, Scanning; Organ Size; Oxalates; Oxazoles; Phosphates; PPAR alpha; PPAR gamma; Proteinuria; Rats; Rats, Sprague-Dawley; Spectrometry, X-Ray Emission; Urinary Bladder Neoplasms; Urolithiasis; Urothelium | 2006 |